The U.S. Food and Drug Administration has authorized Aletta, the first standalone blood draw robot capable of collecting blood from adult patients without hands-on operator intervention, according to an announcement by the agency on August 19, 2026. Developed by Vitestro, the automated phlebotomy system combines near-infrared imaging and Doppler ultrasound to locate veins, apply a tourniquet, insert a needle, and collect samples in outpatient settings.
How the Aletta Robotic Phlebotomy System Operates
According to clinical documentation and company disclosures, the blood draw process begins when a patient inserts labeled collection tubes into the device and places their arm inside the unit. A trained supervising phlebotomist initiates each session, and one professional can oversee up to three Aletta devices simultaneously, according to reporting by iTechPost. The device first uses near-infrared light to find a starting position for its ultrasound probe and sprays 70% alcohol on the skin. Next, the system scans the antecubital area with ultrasound, utilizing Doppler technology to distinguish veins from arteries while analyzing vein depth, size, and orientation. If Aletta fails to identify a suitable vein, it will not attempt the procedure.
Once a viable vein is confirmed, the system applies tourniquet pressure and inserts a 21-gauge, single-use needle at an angle between 10 and 30 degrees, as detailed by Medical Design and Outsourcing. Blood collection tubes connect automatically, and the device inverts each sample immediately after filling a predefined number of times. The median procedure time from initiation to the final bandage application is two minutes, with the needle kept hidden from the patient’s view throughout the draw.
FDA Authorization and Clinical Evidence
The FDA granted marketing authorization through the DeNovo pathway, a regulatory route designated for novel medical devices without an existing equivalent classification. According to agency statements, the authorization relied on clinical data demonstrating that Aletta achieved blood-draw success rates comparable to or better than trained human phlebotomists once needle insertion proceeded. The trial included patients across diverse health conditions, skin tones, and self-reported vein access challenges. Device-related adverse events were classified as uncommon and mild.
Dr. Michelle Tarver, director of the FDA Center for Devices and Radiological Health, noted that blood draws represent one of the most common medical procedures nationwide, yet patients frequently encounter delays driven by a growing shortage of trained phlebotomists. Vitestro expects these capacity constraints to intensify, impacting diagnostic access. The company has secured significant backing to scale the technology, including a $70 million Series B funding round closed in March 2026 with participation from the Mayo Clinic, Labcorp Venture Fund, and Sonder Capital co-founder Fred Moll.
Built-In Safety Protocols and Human Oversight
Despite full automation of the physical draw, Aletta requires continuous human supervision. A healthcare professional remains nearby throughout the session to manage unexpected issues, and the hardware features two red emergency stop buttons. Automated safety sensors halt the procedure immediately if a patient moves excessively, causing the needle to detach automatically. Additional sensors pause the device and alert the supervising staff if other operational concerns arise.
Prior to its U.S. regulatory clearance, Aletta earned CE marking in Europe and initiated deployments in healthcare settings across the continent. With the FDA De Novo authorization now active, Vitestro is positioned to introduce the automated phlebotomy platform into adult outpatient clinical workflows across the United States.
Keep reading